EP0266099A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
Assignee: Johns Hopkins University
•
Filing: 1987-10-15
•
Granted: —
•
Expires: 2007-10-15
Abstract
Abstract A composition for inactivating a target nucleic acid which comprises an oligonucleoside alkyl or arylphosphonate analogue which is complementary to the sequence of the target nucleic acid and includes a functional group which reacts with the target nucleic acid to render the target nucleic acid inactive or nonfunctional.
Inventors
- 👤 Paul S. Miller
- 👤 Paul O.P. Ts'o
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-30 11:26
CPC Classifications
C; C07; C07H; C07H21/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
61 words
A composition for inactivating a target nucleic acid which comprises an oligonucleoside alkyl or arylphosphonate analogue which is complementary to the sequence of the target nucleic acid and includes a functional group which reacts with the target nucleic acid to render the target nucleic acid inactive, the functional group being one which cleaves the target nucleic acid to inactivate the same.
Claim 2
Dependent Claim
61 words
A composition for inactivating a target nucleic acid which comprises an oligonucleoside alkyl or arylphosphonate analogue which is complementary to the sequence of the target nucleic acid and includes a functional group which reacts with the target nucleic acid to render the target nucleic acid inactive, the functional group being one which cleaves the target nucleic acid to inactivate the same.
Claim 3
Dependent Claim
14 words
A composition according to claim 1 wherein the phosphonate analogue is an oligonucleoside methylphosphonate.
Claim 4
Dependent Claim
18 words
A composition according to claim 1 wherein the functional group is derived from a transition metal chelating complex.
Claim 5
Dependent Claim
15 words
A composition according to claim 3 wherein the transition metal chelating complex is ethylene-diamine tetraacetate.
Claim 6
Dependent Claim
14 words
A composition according to claim 3 wherein the transition metal chelating complex is phenanthroline.
Claim 7
Dependent Claim
17 words
A composition according to claim 3 wherein the transition metal chelating complex is a derivative of porphyrin.
Claim 8
Dependent Claim
17 words
A composition according to claim 3 wherein the transition metal chelating complex is a derivative of bleomycin.
Claim 9
Dependent Claim
14 words
A composition according to claim 1 wherein the functional group is an alkylating agent.
Claim 10
Dependent Claim
14 words
A composition according to claim 8 wherein the functional group is an alkyl halide.
Claim 11
Dependent Claim
13 words
A composition according to claim 8 wherein the functional group is a haloacetamide.
Claim 12
Dependent Claim
13 words
A composition according to claim 8 wherein the functional group is a phosphotriester.
Claim 13
Dependent Claim
71 words
A process for inactivating or interferring with the function of undesired or foreign nucleic acid in the presence of otherwise normal living cells which comprises binding the nucleic acid with a derivative of a nonionic oligonucleoside alkyl or arylphosphonate analogue which is complementary to the sequence of the target nucleic acid, said derivatives including a functional group which cleaves the target nucleic acid to prevent the target nucleic acid from functioning.
Claim 14
Dependent Claim
71 words
A process for inactivating or interferring with the function of undesired or foreign nucleic acid in the presence of otherwise normal living cells which comprises binding the nucleic acid with a derivative of a nonionic oligonucleoside alkyl or arylphosphonate analogue which is complementary to the sequence of the target nucleic acid, said derivatives including a functional group which cleaves the target nucleic acid to prevent the target nucleic acid from functioning.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.